Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 82.28
DSCI's Cash-to-Debt is ranked higher than
75% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. DSCI: 82.28 )
Ranked among companies with meaningful Cash-to-Debt only.
DSCI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.65 Max: No Debt
Current: 82.28
Equity-to-Asset 0.62
DSCI's Equity-to-Asset is ranked higher than
58% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. DSCI: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
DSCI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.7 Max: 0.94
Current: 0.62
0.28
0.94
Interest Coverage N/A
DSCI's Interest Coverage is ranked higher than
74% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. DSCI: N/A )
Ranked among companies with meaningful Interest Coverage only.
DSCI' s Interest Coverage Range Over the Past 10 Years
Min: 3.51  Med: No Debt Max: No Debt
Current: N/A
Piotroski F-Score: 3
Altman Z-Score: 1.08
Beneish M-Score: -2.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -14.72
DSCI's Operating Margin % is ranked lower than
72% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. DSCI: -14.72 )
Ranked among companies with meaningful Operating Margin % only.
DSCI' s Operating Margin % Range Over the Past 10 Years
Min: -26  Med: -5.98 Max: 4.71
Current: -14.72
-26
4.71
Net Margin % -10.70
DSCI's Net Margin % is ranked lower than
69% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. DSCI: -10.70 )
Ranked among companies with meaningful Net Margin % only.
DSCI' s Net Margin % Range Over the Past 10 Years
Min: -47.49  Med: -7.41 Max: 2.4
Current: -10.7
-47.49
2.4
ROE % -10.07
DSCI's ROE % is ranked lower than
68% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. DSCI: -10.07 )
Ranked among companies with meaningful ROE % only.
DSCI' s ROE % Range Over the Past 10 Years
Min: -39.24  Med: -14.87 Max: 6.13
Current: -10.07
-39.24
6.13
ROA % -8.11
DSCI's ROA % is ranked lower than
66% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. DSCI: -8.11 )
Ranked among companies with meaningful ROA % only.
DSCI' s ROA % Range Over the Past 10 Years
Min: -34.91  Med: -10.04 Max: 4.65
Current: -8.11
-34.91
4.65
ROC (Joel Greenblatt) % -75.18
DSCI's ROC (Joel Greenblatt) % is ranked lower than
75% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. DSCI: -75.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DSCI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -114.31  Med: -22.71 Max: 14.74
Current: -75.18
-114.31
14.74
3-Year Revenue Growth Rate -17.40
DSCI's 3-Year Revenue Growth Rate is ranked lower than
85% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. DSCI: -17.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DSCI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -39.8  Med: -11.8 Max: 10.8
Current: -17.4
-39.8
10.8
3-Year EBITDA Growth Rate -7.80
DSCI's 3-Year EBITDA Growth Rate is ranked lower than
77% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. DSCI: -7.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DSCI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -76.7  Med: -0.4 Max: 163.8
Current: -7.8
-76.7
163.8
3-Year EPS without NRI Growth Rate -6.60
DSCI's 3-Year EPS without NRI Growth Rate is ranked lower than
69% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. DSCI: -6.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DSCI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -6.9 Max: 57.1
Current: -6.6
0
57.1
GuruFocus has detected 5 Warning Signs with Derma Sciences Inc $DSCI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DSCI's 30-Y Financials

Financials (Next Earnings Date: 2017-06-16 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

DSCI Guru Trades in Q2 2016

Jim Simons 579,700 sh (+7.00%)
Chuck Royce 232,521 sh (-2.10%)
» More
Q3 2016

DSCI Guru Trades in Q3 2016

Chuck Royce 332,521 sh (+43.01%)
Jim Simons 638,000 sh (+10.06%)
» More
Q4 2016

DSCI Guru Trades in Q4 2016

Chuck Royce 549,341 sh (+65.20%)
Jim Simons 629,600 sh (-1.32%)
» More
Q1 2017

DSCI Guru Trades in Q1 2017

Jim Simons Sold Out
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DSCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 621610    SIC: 3841
Compare:NAS:CFMS, NAS:UTMD, NAS:SIEN, NAS:IVTY, NAS:ENTL, NAS:MBOT, NAS:LAKE, NAS:HBIO, NAS:BIOL, AMEX:TRXC, AMEX:BVX, NAS:LENS, AMEX:MLSS, AMEX:RVP, NAS:VLRX, AMEX:INFU, AMEX:ISR, NAS:BLFS, NAS:EKSO, NAS:CASM » details
Headquarter Location:USA
Derma Sciences Inc is a tissue regeneration company engaged in pharmaceutical wound care, advanced wound care and traditional wound care products.

Derma Sciences Inc was incorporated on September 10, 1984. The Company is a tissue regeneration company engaged in three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. The Company has one drug candidate that initiated its Phase 3 study. The Company maintains manufacturing facilities in Toronto, Canada and Nantong, China and an established network of third party suppliers for its products. Its products are sold through distributors to health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians' offices. Some of its products are sold through retail channels to care givers. The Company markets its products through direct sales representatives in the United States, Canada and the United Kingdom, and through independent distributors within other select international markets. In Pharmaceutical Wound Care, the DSC127 product is in clinical trial for the treatment of diabetic foot ulcers. The Phase 3 clinical trial for diabetic foot ulcers is expected to be completed by the end of 2015. In addition to the diabetic foot ulcer indication, the Company has begun preclinical testing for scar reduction. The product lines in Advanced Wound Care include MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB, BIOGUARD, and ALGICELL AG. The Traditional Wound Care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. It also manufactures and market adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. It markets a line of wound closure strips, nasal tube fasteners and a variety of catheter fasteners to doctors, clinics, nursing homes, hospitals and other institutions. In addition, the Company owns or licenses over 50 U.S. patents, corresponding foreign patents and patent applications. The patents relating to the DSC127, MEDIHONEY, BIOGUARD, AMNIOEXCEL and AMNIOMATRIX technologies are held under license agreements of indefinite duration. It is subject to the regulation regarding occupational safety, laboratory practices, environmental protection and hazardous substance control and may be subject to other present and future U.S. and foreign regulations.

Ratios

vs
industry
vs
history
Forward PE Ratio 100.00
DSCI's Forward PE Ratio is ranked lower than
99% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.42 vs. DSCI: 100.00 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.76
DSCI's PB Ratio is ranked higher than
75% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. DSCI: 1.76 )
Ranked among companies with meaningful PB Ratio only.
DSCI' s PB Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.46 Max: 3.42
Current: 1.76
0.5
3.42
PS Ratio 1.88
DSCI's PS Ratio is ranked higher than
68% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. DSCI: 1.88 )
Ranked among companies with meaningful PS Ratio only.
DSCI' s PS Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.98 Max: 3.25
Current: 1.88
0.2
3.25
Current Ratio 1.29
DSCI's Current Ratio is ranked lower than
81% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. DSCI: 1.29 )
Ranked among companies with meaningful Current Ratio only.
DSCI' s Current Ratio Range Over the Past 10 Years
Min: 1.05  Med: 2.39 Max: 15.92
Current: 1.29
1.05
15.92
Quick Ratio 1.02
DSCI's Quick Ratio is ranked lower than
76% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. DSCI: 1.02 )
Ranked among companies with meaningful Quick Ratio only.
DSCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.33 Max: 13.56
Current: 1.02
0.4
13.56
Days Inventory 115.06
DSCI's Days Inventory is ranked higher than
57% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. DSCI: 115.06 )
Ranked among companies with meaningful Days Inventory only.
DSCI' s Days Inventory Range Over the Past 10 Years
Min: 85.54  Med: 109.46 Max: 130.4
Current: 115.06
85.54
130.4
Days Sales Outstanding 40.10
DSCI's Days Sales Outstanding is ranked higher than
89% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. DSCI: 40.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
DSCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.37  Med: 35.19 Max: 40.1
Current: 40.1
25.37
40.1
Days Payable 19.75
DSCI's Days Payable is ranked lower than
93% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. DSCI: 19.75 )
Ranked among companies with meaningful Days Payable only.
DSCI' s Days Payable Range Over the Past 10 Years
Min: 17.45  Med: 32.99 Max: 66.29
Current: 19.75
17.45
66.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.10
DSCI's 3-Year Average Share Buyback Ratio is ranked lower than
79% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. DSCI: -16.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DSCI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -66.3  Med: -34.9 Max: 4.2
Current: -16.1
-66.3
4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 233.33
DSCI's Price-to-Net-Current-Asset-Value is ranked lower than
98% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.18 vs. DSCI: 233.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
DSCI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.52  Med: 2.83 Max: 233.34
Current: 233.33
0.52
233.34
Price-to-Tangible-Book 8.64
DSCI's Price-to-Tangible-Book is ranked lower than
75% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. DSCI: 8.64 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DSCI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.42  Med: 2 Max: 9.88
Current: 8.64
0.42
9.88
Price-to-Median-PS-Value 1.92
DSCI's Price-to-Median-PS-Value is ranked lower than
82% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. DSCI: 1.92 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DSCI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.66 Max: 2.99
Current: 1.92
0.07
2.99
Earnings Yield (Greenblatt) % -9.11
DSCI's Earnings Yield (Greenblatt) % is ranked lower than
85% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. DSCI: -9.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DSCI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.11  Med: 2.7 Max: 6.7
Current: -9.11
-9.11
6.7

More Statistics

Revenue (TTM) (Mil) $97.36
EPS (TTM) $ -0.40
Short Percentage of Float0.76%
52-Week Range $2.92 - 7.05
Shares Outstanding (Mil)28.27

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 91 108 120
EPS ($) -0.10 0.07 0.20
EPS without NRI ($) -0.10 0.07 0.20
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for DSCI

Headlines

Articles On GuruFocus.com
Derma Sciences Inc. Reports Operating Results (10-Q) Nov 12 2010 
Derma Sciences Inc. Reports Operating Results (10-Q) May 12 2010 

More From Other Websites
Why One Analyst Sees Almost 40% Upside in Integra LifeSciences Apr 03 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Derma... Jan 27 2017
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of... Jan 20 2017
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences,... Jan 17 2017
Harwood Feffer LLP Announces Investigation of Derma Sciences Inc. Jan 17 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of... Jan 17 2017
DERMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Derma Sciences, Inc.... Jan 13 2017
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences,... Jan 12 2017
Integra LifeSciences Buys Derma Sciences for $204M Jan 12 2017
DERMA SCIENCES, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition... Jan 12 2017
Company News for January 12, 2017 Jan 12 2017
Blog Coverage Integra Set to Acquire Derma Sciences; Announced Outlook 2017 Jan 12 2017
Derma Sciences Buys MEDIHONEY® Brand From Long-Term Partner Jan 11 2017
Wednesday’s Top Biopharma Movers Jan 11 2017
Derma Sciences Soars Almost 40% on Buyout by Integra Jan 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)